TABLE. Estimated dengue virus immunoglobulin G seroprevalence among children and adolescents aged 7–16 years — American Samoa, September–October 2023.
| Characteristic | No. of participants tested* | No. of participants with positive test results | Estimated IgG seroprevalence, % (95% CI)† |
|---|---|---|---|
|
Total, aged 7–16 yrs
|
887
|
492
|
59 (47–71)
|
|
Age-eligible for vaccination, 9–16 yrs
|
767
|
437 |
60 (48–72) |
|
Age, yrs
| |||
| 7 |
17
|
9 |
84 (26–100) |
| 8 |
103
|
46 |
46 (32–60) |
| 9 |
100
|
52 |
59 (37–80) |
| 10 |
124
|
71 |
53 (25–81) |
| 11 |
115
|
72 |
67 (50–84) |
| 12 |
127
|
66 |
53 (34–71) |
| 13 |
135
|
85 |
72 (56–88) |
| 14 |
102
|
56 |
58 (28–88) |
| 15 |
61
|
32 |
55 (17–94) |
| 16 |
3
|
3 |
100 (—) |
|
Sex§
| |||
| Female |
475
|
273 |
61 (49–74) |
| Male | 411 | 219 | 56 (44–74) |
Abbreviation: IgG = immunoglobulin G.
* Twenty-four participants received uninterpretable test results: males (14); and children and adolescents aged 7 years (three), 8 years (two), 9 years (two), 10 years (two), 11 years (six), 12 years (four), 13 years (three), 14 years (one), and 15 years (one).
† Seroprevalence was estimated using survey weights and adjusted for sensitivity and specificity.
§ One participant did not specify their sex.